Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma

Authors

Jason R Westin, The University of Texas MD Anderson Cancer Center
Armin Ghobadi, Washington University School of Medicine in St. Louis
et al.

Journal

Clinical cancer research

Publication Date

5-15-2023

Volume

29

Issue

10

First Page

1894

Last Page

1905

Document Type

Open Access Publication

DOI

10.1158/1078-0432.CCR-22-3136

Rights and Permissions

Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res. 2023 May 15;29(10):1894-1905. doi: 10.1158/1078-0432.CCR-22-3136 This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Recommended Citation

Westin, Jason R; Ghobadi, Armin; and et al., "Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma." Clinical cancer research. 29, 10. 1894 - 1905. (2023).
https://digitalcommons.wustl.edu/oa_4/2013

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.